12:00 AM
May 16, 2016
 |  BC Week In Review  |  Company News  |  Other News

Clovis cancer news

Clovis will reduce staff and contractor positions by 35% by year end compared to the end of 2015 and will reprioritize resources from rociletinib to its next most-advanced candidate, rucaparib. Clovis stopped enrollment in all studies of rociletinib, including the confirmatory Phase III TIGER-3 trial, and withdrew an MAA for the compound. The company said it expects FDA to issue a complete response letter for an NDA for rociletinib following last month’s 12 to one vote by...

Read the full 364 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >